ArticleACS central science2025
A Small Molecule Drug-Based Ru(II) Polypyridine Mass-Tag for Multimodal Imaging of Tissue Samples.
Article in ACS central science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- TyrRu: A Tyramide-Amplified Multimodal Ruthenium Tag for Elemental Mass Spectrometry and Immunofluorescence Imaging.Chemical & biomedical imaging · 2026Article
- Exploring chemical space for iridium(iii) complexes: a direct-to-biology (D2B) approach to identifying anticancer and antibacterial agents.Chemical science · 2026Article
- A photocleavable peptidic Ru(ii) mass-tag enabling targeted DESI and MALDI mass spectrometry imaging in cancer tissues.Chemical science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mass spectrometry imaging (MSI) is a powerful tool for spatially resolved multiomics analysis of tissue samples in clinical research. However, its proteomics application is still limited due to challenges such as low ionization efficiency and signal interference from complex tissue environments. On-tissue mass-tag labeling (OTMT) addresses these limitations using affinity-based imaging agents that incorporate cleavable, highly ionizable reporter groups known as mass-tags (MTs). The majority of existing MTs rely on antibodies as targeting elements and organic moieties as reporter groups. Here, we introduce a new class of MTs featuring small-molecule inhibitors as binding motifs. Specifically, we present
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.